After raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets | BioPharma Dive
Dive Brief: - Parabilis Medicines, a well-funded startup that is advancing a science it believes can reach “undruggable” targets in oncology, on Tuesday filed papers outlining an initial public offering. - The…
Read guide →